press releases
DreaMed Secures Landmark FDA Clearance for MODI
First FDA-cleared CGM-informed automatic insulin titration solution for people with type 2 diabetes using both basal-only and multiple daily injection treatment regimens. PETAH TIKVA, Israel – [MONTH DAY, 2026] – DreaMed Diabetes Ltd. today announced that the U.S. Food and Drug Administration has granted 510(k) clearance to MODI, establishing the first FDA-cleared insulin therapy adjustment […]